Last reviewed · How we verify
patch + lozenge
A nicotine replacement therapy combining transdermal patch and oral lozenge delivery to reduce cigarette cravings and withdrawal symptoms during smoking cessation.
A nicotine replacement therapy combining transdermal patch and oral lozenge delivery to reduce cigarette cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation in adults.
At a glance
| Generic name | patch + lozenge |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Drug class | Nicotine replacement therapy (NRT) |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Smoking Cessation / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
The patch provides steady-state nicotine levels throughout the day via transdermal absorption, while the lozenge delivers rapid nicotine to the oral mucosa for acute craving relief. Together, they maintain consistent nicotine exposure while allowing flexible dosing for breakthrough cravings, reducing reliance on cigarettes.
Approved indications
- Smoking cessation in adults
Common side effects
- Skin irritation at patch site
- Mouth/throat irritation from lozenge
- Hiccups
- Nausea
- Insomnia
- Headache
Key clinical trials
- Partnering With Food Bank to Provide Tobacco Treatment to Underserved Smokers (NA)
- Using MASL to Combat Oral Cancer (EARLY_PHASE1)
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- Cytisine vs Nicotine Replacement Therapy (NA)
- ACT Lung Health Intervention: Phase Two (NA)
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |